Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas

被引:111
作者
Alò, PL
Visca, P
Trombetta, G
Mangoni, A
Lenti, L
Monaco, S
Botti, C
Serpieri, DE
Di Tondo, U
机构
[1] Univ Rome La Sapienza, Dipartimento Med Sperimentale & Pathol, I-00161 Rome, Italy
[2] Regina Elena Canc Inst, Serv Citodiagnost, Rome, Italy
[3] Regina Elena Canc Inst, Dipartimento Chirurg, Rome, Italy
关键词
fatty acid synthase; breast carcinoma; prognosis;
D O I
10.1177/030089169908500108
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background: Many normal and human cancer tissues express fatty acid synthase (FAS), the major enzyme required for endogenous fatty acid biosynthesis. Strong expression of FAS seems to be associated with a poor prognosis. This study examines the strength of FAS and other common markers of relapse in poorly differentiated breast carcinoma. Materials and methods: Fifty-one patients with poorly differentiated ductal infiltrating breast carcinomas were followed up for more than 10 years. Immunohistochemical detection of FAS was associated with morphological features of the tumors, with immunohistochemical expression of c-erbB-2, cathepsin D, estrogen and progesterone receptor status and with DNA ploidy in order to detect a statistical correlation, Results: The chi-square test revealed a correlation between FAS and peritumoral lymphatic vessel invasion (PLVI) (P = 0.001). Univariate analysis showed that FAS was correlated with disease-free survival (DFS) (P=0.0001), Other prognosticators associated with DFS were PLVI (P = 0.002), estrogen (P = 0.008) and progesterone receptor status (P = 0.007), Bivariate analysis showed that FAS was a further prognostic discriminant of DFS within the ER, PgR and PLVI subsets. Discussion: FAS is a reliable prognosticator of recurrence in poorly differentiated early breast carcinomas, Association of FAS with PLVI may be useful to plan a correct follow-up in patients with breast neoplasms.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 49 条
  • [1] C-ERBB-2 ONCOGENE IN BREAST-CANCER - THE RIGHT TARGET OR A DECOY
    ANDERSON, TJ
    [J]. HUMAN PATHOLOGY, 1992, 23 (09) : 971 - 972
  • [2] [Anonymous], 1983, APPL STAT
  • [3] IMMUNOHISTOCHEMICAL DETECTION OF CATHEPSIN-D IN T(2)N(0)M(0) BREAST-CARCINOMA
    ARMAS, OA
    GERALD, WL
    LESSER, ML
    ARROYO, CD
    NORTON, L
    ROSEN, PP
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (02) : 158 - 166
  • [4] BACUS SS, 1990, AM J PATHOL, V137, P103
  • [5] CATHEPSIN D ASSAY IN PRIMARY BREAST-CANCER AND LYMPH-NODES - RELATIONSHIP WITH C-MYC, C-ERB-B-2 AND INT-2 ONCOGENE AMPLIFICATION AND NODE INVASIVENESS
    BROUILLET, JP
    THEILLET, C
    MAUDELONDE, T
    DEFRENNE, A
    SIMONYLAFONTAINE, J
    SERTOUR, J
    PUJOL, H
    JEANTEUR, P
    ROCHEFORT, H
    [J]. EUROPEAN JOURNAL OF CANCER, 1990, 26 (04) : 437 - 441
  • [6] CATHEPSIN-D AND BREAST-CANCER - USEFUL
    CARDIFF, RD
    [J]. HUMAN PATHOLOGY, 1994, 25 (09) : 847 - 848
  • [7] PROGESTIN-INDUCED FATTY-ACID SYNTHETASE IN BREAST-CANCER - FROM MOLECULAR-BIOLOGY TO CLINICAL-APPLICATIONS
    CHALBOS, D
    JOYEUX, C
    ESCOT, C
    GALTIER, F
    ROCHEFORT, H
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 595 : 67 - 73
  • [8] CHU KC, 1996, J NATL CANCER I, V18, P1791
  • [9] CLEMENTE CG, 1992, CANCER-AM CANCER SOC, V69, P1396, DOI 10.1002/1097-0142(19920315)69:6<1396::AID-CNCR2820690615>3.0.CO
  • [10] 2-I